Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Durham, North Carolina

Phase 1 cancer trials in Durham, NC

63 Phase 1 cancer studies are recruiting participants at sites in Durham as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Durham at a glance

Breast cancer studies recruiting in Durham

Basic details from each study's public record (the 30 most recently updated of 63). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Duke Cancer Institute
    Registry record
    NCT06253871 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Duke Cancer Center Durham
    Registry record
    NCT07488676 · updated
  3. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Duke Cancer Institute
    Registry record
    NCT03424005 · updated
  4. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Duke Cancer Institute
    Registry record
    NCT05315700 · updated
  5. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Duke University Medical Center
    Registry record
    NCT07213791 · updated
  6. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Duke Cancer Center
    Registry record
    NCT06120283 · updated
  7. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Duke Cancer Center /ID# 255129
    Registry record
    NCT06084481 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Lung cancer studies recruiting in Durham

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Duke University School of Medicine
    Registry record
    NCT05786924 · updated
  2. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Duke University Medical Center
    Registry record
    NCT04886804 · updated
  3. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study site
    Duke University
    Registry record
    NCT07491497 · updated
  4. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Duke Cancer Institute
    Registry record
    NCT06706076 · updated
  5. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    Duke Health - Duke University Hospital
    Registry record
    NCT05856981 · updated
  6. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  7. A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Zai Lab (Shanghai) Co., Ltd.
    Study site
    Duke University
    Registry record
    NCT06179069 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Durham

  1. TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Duke University Medical Center
    Registry record
    NCT07190300 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Duke University Medical Center Duke Cancer Center
    Registry record
    NCT04221542 · updated
  3. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Duke University Medical Center
    Registry record
    NCT06800313 · updated
  4. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    K36 Therapeutics, Inc.
    Study site
    Duke Cancer Center
    Registry record
    NCT07103018 · updated
  5. A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Duke Univ Medical Center
    Registry record
    NCT07226986 · updated
  6. An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Duke University Medical Center
    Registry record
    NCT07206056 · updated
  7. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Duke University
    Registry record
    NCT05919264 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Melanoma studies recruiting in Durham

  1. A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duke University
    Study site
    Duke University Medical Center
    Registry record
    NCT05077137 · updated
  2. IL-17 Blockade to Decrease irAEs (REPLAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duke University
    Study site
    Duke University Health System
    Registry record
    NCT07237594 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Durham, NC on ClinicalTrials.gov.

Lymphoma studies recruiting in Durham

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Duke University Medical Center
    Registry record
    NCT04726241 · updated
  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Duke University Medical Center
    Registry record
    NCT05384626 · updated
  3. Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

    • Phase 1/2
    • Ages 16 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07155226 · updated
  4. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    • Phase 1/2
    • From 30 days
    • All sexes
    Sponsor
    Syndax Pharmaceuticals
    Study site
    Duke University Medical Center
    Registry record
    NCT04065399 · updated
  5. CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Curis, Inc.
    Study site
    Duke University Medical Center, Duke Cancer Center
    Registry record
    NCT03328078 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Durham, NC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Durham

  1. A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Duke University Medical Center - Duke Cancer Center
    Registry record
    NCT07024615 · updated
  2. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Ask about studies near Durham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call